Feb 6, 2017
Amgen Announces the Efficacy of Repatha® (Evolocumab) for Reducing The Risk Of Cardiovascular Events Feb. 2, 2017 Amgen has announced that the FOURIER (Further Cardiovascular OUtcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) trial evaluating whether Repatha® (evolocumab) minimizes the risk of cardiovascular events in patients with clinically evident atherosclerotic cardiovascular disease (ASCVD) met its primary composite endpoint (cardiovascular death, non-fatal stroke, non-fatal myocardial infarction (MI), coronary revascularization or hospitalization for unstable angina) and the key secondary composite endpoint (cardiovascular death, non-fatal stroke or non-fatal MI).